Beckman Coulter Life Sciences is expanding their flow cytometry portfolio with the addition of 14 new human monoclonal antibodies from Trillium Diagnostics LLC. The analyte specific reagents (ASRs) provide high specificity, convenience and flexibility in flow cytometry. A new cell permeabilization reagent is also being offered.
The new monoclonals include human anti-hemoglobin F, which recognises a fetal hemogloblobin molecule; CD163 markers for anti-inflammatory signal and disease process research; and CD64 markers, which react with Fc gamma receptor 1 and binds human IgG1 and IgG3. Characterised, quality controlled, convenient, liquid reagents allow users to spend less time in sample preparation and more time on experiments.
Rounding out the line is a monoclonal for MNDA (myeloid nuclear differentiation antigen). All antibodies are available unconjugated or conjugated to a selection of fluorochromes. Intra-Cell™ concentrate for cell permeabilization is also being released.
Beckman Coulter Life Sciences offers an extensive line of human and non-human antibodies as well as a range of supporting reagents and immune monitoring products. The new antibodies are supplied in 1.0mL of buffer, are ready to use and facilitate flexibility in experimental design.
“Convenience and specificity are important features for scientists,” said Mario Koksch, Director of Strategy and Portfolio Management for Beckman Coulter Life Sciences. “These new antibodies are directed at important targets and will improve accuracy for researchers.”
A strategic partnership between the companies enables Beckman Coulter Life Sciences to further diversify their extensive flow cytometry reagent portfolio and Trillium Diagnostics to broaden the reach of their products in the global market.
